CN115040591A

CN115040591A - Auxiliary blood pressure reducing composition and application thereof

Info

Publication number: CN115040591A
Application number: CN202210707723.XA
Authority: CN
Inventors: 汪玉芳; 贺瑞坤; 张旭光; 岳中宝; 胡明华
Original assignee: BY Health Co Ltd
Current assignee: BY Health Co Ltd
Priority date: 2022-06-21
Filing date: 2022-06-21
Publication date: 2022-09-13
Anticipated expiration: 2042-06-21
Also published as: CN115040591B

Abstract

The invention discloses an auxiliary blood pressure lowering composition and application thereof, and belongs to the field of medicines, health-care foods or foods. The composition comprises the following components in parts by weight: 3-5 parts of cinnamon extract, 10-20 parts of eucommia ulmoides extract, 10-20 parts of sophora flower extract, 5-10 parts of grape seed extract and 25-30 parts of cocoa extract. The composition can adjust the levels of Ang II, ET-1 and NO in serum by the compounding effect of the components, and the components have synergistic effect, so that the composition has an excellent function of reducing blood pressure.

Description

Auxiliary blood pressure reducing composition and application thereof

Technical Field

The invention belongs to the field of medicines, health-care foods or foods, and relates to an auxiliary blood pressure reducing composition and application thereof.

Background

With age, the prevalence of hypertension and the degree of vascular aging increase. Hypertension and vascular aging are risk factors for the development of atherosclerosis, which leads to increased cardiovascular disease and mortality. Hypertension is a major risk factor of cardiovascular diseases, is a common disease with high incidence worldwide, seriously harms human health, and is clinically characterized in that the systemic arterial pressure exceeds a normal value. At present, a lot of medicines for preventing and treating hypertension are clinically applied, and although the medicines can effectively reduce the blood pressure, the side effects are large, and the fluctuation is large in the blood pressure reduction process. Therefore, the screening and research of the functional food factor with the function of reducing blood pressure have important significance.

In the hypertension detection indexes, Endothelin (ET) and Nitric Oxide (NO) are a pair of vasoactive substances with antagonistic effect, vascular endothelial cells secrete ET and NO simultaneously according to a certain proportion, the ET and the NO maintain normal vascular tension in dynamic balance, and the ET and the NO are the main factors for regulating vascular tension and maintaining stable blood pressure, and if the ET and the NO are in imbalance, essential hypertension can be caused. ACE is a dependent carboxydipeptidase, is a membrane-integrated single-chain glycoprotein, can convert low-activity decapeptide angiotensin I (ngiotensin I, Ang I) into Ang II under the action of ACE, and AT1R in Ang II can play a role in vasoconstriction, vascular smooth muscle proliferation and function and water-salt metabolism regulation.

Chinese patent application 201910210079.3 discloses a composition with blood pressure lowering effect and application thereof, wherein the composition comprises the following components in parts by weight: 10-50 parts of cassia seed, 10-30 parts of medlar, 10-50 parts of gardenia, 10-50 parts of tuckahoe, 5-10 parts of ginger, 10-50 parts of kudzu root, 10-50 parts of dandelion, 10-50 parts of yam and 10-50 parts of chicory. The composition has the effects of treating hypertension, repairing blood vessels, protecting liver, cleaning garbage in blood vessels, intestines and stomach, kidney and liver, and is beneficial to treating hypertension patients. However, the compositions disclosed above have not been studied for the mechanism of lowering blood pressure, nor have the effect of lowering blood pressure been quantified.

Chinese patent application 201911332420.9 discloses a composition with blood pressure lowering effect, which comprises the following raw material components in parts by weight: 5-15 parts of soybean peptide, 1-3 parts of raspberry extract, 1-3 parts of rhodiola extract, 1-3 parts of polygonatum extract, 1-3 parts of grape seed extract, 1-3 parts of green tea extract, 1-3 parts of moringa oleifera leaf extract, 0.5-2 parts of theanine, 0.5-2 parts of astaxanthin, 0.5-2 parts of lycopene, 0.5-2 parts of resveratrol, 0.5-2 parts of curcumin, 0.1-1 part of EPA, 0.1-1 part of DHA, 0.1-1 part of cyanidin and 0.1-1 part of delphinidin; the synergistic antihypertensive drug can not only play a role in lowering blood pressure and effectively reduce the blood pressure of a hypertensive so as to keep the blood pressure of the hypertensive in a stable state for a long time, but also play a role in synergistic effect in lowering cholesterol and blood fat and improving the antioxidant function, relieve and improve the functions of blood vessels, improve the immunity of organisms, remove substances deposited in the blood vessels and blocking the blood vessels, and relieve and improve the occurrence and development of hypertension. However, the composition disclosed above has a large formulation and complicated raw material components.

Therefore, there is a need for a composition that is simple in raw material components, low in cost, and effective in lowering blood pressure.

Disclosure of Invention

Aiming at the problems in the prior art, the invention provides the auxiliary blood pressure reducing composition which is wide in component source, low in cost and good in treatment effect and the application thereof.

In order to achieve the purpose, the technical scheme adopted by the invention is as follows:

first, a composition is provided that includes a cinnamon extract, an eucommia ulmoides extract, a sophora flower extract, a grape seed extract, a cocoa extract.

Further, the composition comprises the following components in parts by weight: 3-5 parts of cinnamon extract, 10-20 parts of eucommia ulmoides extract, 10-20 parts of sophora flower extract, 5-10 parts of grape seed extract and 25-30 parts of cocoa extract.

Further, the weight ratio of the cinnamon extract, the eucommia ulmoides extract and the sophora flower extract is 3-5:10-20: 10-20.

Preferably, the weight ratio of the cinnamon extract, the eucommia ulmoides extract and the sophora flower extract is 4-5:12-18: 12-18.

Further, the weight ratio of the grape seed extract to the cocoa extract is 5-10: 25-30.

Preferably, the weight ratio of the grape seed extract to the cocoa extract is 6-10: 27-28.

Further, the preparation method of the composition is to simply mix all the raw materials according to the weight ratio.

Secondly, the application of the composition in preparing products with the function of reducing blood pressure is provided.

Further, the blood pressure reduction means that Ang II in serum is reduced, ET-1 in serum is reduced, and/or NO in serum is increased, the Ang II is angiotensin II, the ET-1 is endothelin-1, and the NO is nitric oxide.

Furthermore, the mechanism of lowering blood pressure is to regulate the function of vascular endothelium by regulating the generation and release of Ang II, ET-1 and NO, so that blood pressure is lowered by vasodilatation.

Further, the product is any one of a medicine, a dietary supplement and a health food.

Furthermore, the product is in any one of tablets, capsules and powder.

Furthermore, the product can be added with five ingredients of cinnamon extract, eucommia bark extract, sophora flower extract, grape seed extract and cocoa extract, and can also be added with auxiliary materials, wherein the auxiliary materials comprise one or more of filling agent, disintegrating agent, adhesive and wetting agent.

Further, the filler comprises one or more of magnesium stearate, maltodextrin, starch, corn starch, pregelatinized starch, dextrin and microcrystalline cellulose.

Further, the disintegrant comprises one or more of croscarmellose sodium, crospovidone, sodium starch glycolate and low-substituted hydroxypropyl cellulose.

Further, the adhesive comprises one or more of hydroxypropyl methylcellulose, povidone, starch slurry, dextrin, sugar powder and syrup, sodium carboxymethyl cellulose, hydroxypropyl cellulose and microcrystalline cellulose.

Further, the wetting agent comprises one or more of magnesium stearate, polyethylene glycol and sodium lauryl sulfate.

The components of the composition provided by the invention are as follows: the effective component cinnamaldehyde of cortex Cinnamomi has blood vessel dilating effect; the vasodilating effect of pinoresinol diglucoside and quercetin in the extracts of eucommia ulmoides and sophora japonica has endothelium dependence, and is mainly used for relaxing blood vessels by promoting endothelial cells to release NO, and at high concentration, is mainly used for inhibiting Ca of vascular smooth muscle cells ²⁺ The pathways dilate blood vessels; the grape seed extract can antagonize the artery constriction effect of histamine or prostaglandin, and inhibit the activity of Angiotensin Converting Enzyme (ACE), thereby reducing and maintaining normal blood pressure; cocoa extracts can dilate blood vessels by increasing NO and inhibiting ACE; the folium Ginkgo extract has effects of dilating blood vessel, improving peripheral blood circulation, and reducing serum cholesterol; folium Mori can inhibit activity of angiotensin converting enzyme and promote blood pressure decrease.

Compared with the prior art, the invention has the following beneficial effects:

(1) the auxiliary blood pressure reducing composition can adjust the levels of Ang II, ET-1 and NO in serum by the compounding effect of the components, and the components have synergistic effect, so that the composition has an excellent blood pressure reducing function;

(2) the composition has the advantages of wide raw material source, simple preparation method and low production cost.

Detailed Description

It should be noted that the raw materials used in the present invention are all common commercial products, and the sources thereof are not particularly limited.

The following reagents and instrument sources are illustrative:

cinnamon extract, eucommia bark extract, sophora flower extract, provided by Guangdong Qingyun Yam industry Co., Ltd; grape seed extract is provided by Ningbo Chinese medicinal pharmacy, Inc.; cocoa extracts are provided by nanopattern corporation; folium Ginkgo extract and folium Mori extract are provided by Guangdong Qingyun Yam industry Co. Captopril manufacturer: changzhou pharmaceutical factory Co., Ltd; 0.5% CMC-Na (sodium carboxymethylcellulose) was supplied by Tianjin Damao chemical reagent factory; BP-2010A Intelligent non-invasive sphygmomanometer manufacturer: beijing Chuolong Biotechnology Ltd.

Preparation of the compositions of examples 1-4, comparative examples 1-6: the raw materials are mixed evenly according to the weight ratio.

Examples 1 to 4 and comparative examples 1 to 6

The formulations of example 14 and comparative examples 1 to 6 are shown in Table 1:

TABLE 1

Examples of the experiments

Test animals: after 7 days of quarantine, non-invasive rat tail blood pressure and heart rate test (see tables 2 and 3) were performed on day 0 using a BP-2010A intelligent non-invasive sphygmomanometer in 10 Wistar-Kyoto rats (WKY) and 120 male Spontaneous Hypertensive Rats (SHR), 10 WKY rats were divided into normal groups, and 120 SHR rats were randomly grouped by blood pressure, and they were respectively a model group, an example 1 group, an example 2 group, an example 3 group, an example 4 group, a comparative example 1 group, a comparative example 2 group, a comparative example 3 group, a comparative example 4 group, a comparative example 5 group, a comparative example 6 group, and a positive drug captopril group, each group consisting of 10 rats. The normal group and the model group were given 10mL/kg of 0.5% CMC-Na, and each treatment group was given 10mL/kg of the corresponding test sample amount. The tail artery systolic blood pressure and heart rate tests before and after administration at 7d, 14d, 21d and 30d are shown in tables 2 and 3.

Data processing: the blood pressure measurement data is measured and analyzed by t-test. The self-contrast data can adopt a pair t test, two groups of mean comparison adopt a group t test, the latter needs to carry out a homogeneity test of variance, the non-normal distribution or the data with uneven variance are subjected to proper variable conversion, and after the normal variance is met, the converted data is used for carrying out the t test; if the converted data can not meet the requirement of normal variance, the t test or the rank sum test is adopted; but data with too large a coefficient of variation (e.g., CV > 50%) apply rank-sum tests.

And (4) judging a result: the blood pressure of the animals in the experimental group is obviously lower than that of the animals in the model control group, the difference is significant, the heart rate of the animals in the experimental group and the blood pressure and heart rate of normal animals are not affected, and the positive experimental result of the functional animals which are beneficial to maintaining the healthy level of the blood pressure can be judged.

Results

TABLE 2 Effect of test samples on rat systolic pressure (X + -SD)

Note: comparison with model group,: p <0.05, x: p < 0.01.

As shown in Table 2, the systolic blood pressure of the model group animals was significantly increased (P <0.01) from 0 to 30d as compared with the normal group. Compared with the model group, the systolic blood pressure of animals in 7d and 14d positive groups is obviously reduced after the test sample is given (P < 0.01); 21d, 30d animals of examples 1-4 and positive groups showed significant reduction in systolic blood pressure (P < 0.01).

Table 3 heart rate variability (n 10, times/min) in each group of rats during the functional test of assisting hypotension (X ± SD)

Note: comparison with model group,: p <0.05, x: p < 0.01.

As shown in Table 3, in 0-30d, there was no statistical difference in the heart rate of the model group rats compared to the normal group (P > 0.05); compared with the model group, the heart rate of rats in each test sample group and the positive group is not statistically different (P > 0.05).

TABLE 4 Effect of test samples on the levels of Ang II, NO, ET-1 in the serum of SHR rats (X + -SD)

Note: comparison with model group,: p <0.05, x: p < 0.01.

Table 4 shows the change of Ang II, NO and ET-1 levels in serum of SHR rats after the experimental period of auxiliary blood pressure lowering function is finished. From table 4, it can be seen that after 30d of the test sample, the levels of Ang II and endothelin (ET-1) in the serum of the model rat are significantly increased (P <0.05 or P <0.01) and the level of NO is significantly decreased (P <0.05) compared to the normal group. Compared with the model group, the serum levels of Ang II of the rats of examples 1-4 are significantly reduced (P <0.05 or P <0.01), the levels of NO are significantly increased (P <0.05 or P <0.01), and the levels of ET-1 are significantly reduced (P <0.05 or P < 0.01).

Under the experimental conditions, after the SHR rat test sample is administered for 30d, the groups of examples 1-4 significantly reduce the blood pressure of the Spontaneous Hypertensive Rat (SHR), and the pressure reduction mechanism is related to the regulation of the levels of Ang II, NO and ET-1 in the serum of the SHR rat, which shows that the blood pressure can be reduced by regulating the generation and release of Ang II, NO and ET-1 to regulate the function of vascular endothelium and relax blood vessels. The cinnamon extract, the eucommia bark extract and the sophora flower extract are compounded, the grape seed extract and the cocoa extract are compounded, and the effect is optimal when the dosage ratio of the components is within the protection range of the application.

Finally, it should be noted that the above-mentioned contents are only used for illustrating the technical solutions of the present invention, and not for limiting the protection scope of the present invention, and that the simple modifications or equivalent substitutions of the technical solutions of the present invention by those of ordinary skill in the art can be made without departing from the spirit and scope of the technical solutions of the present invention.

Claims

1. A composition comprising cinnamon extract, eucommia ulmoides extract, sophora flower extract, grape seed extract, cocoa extract.

2. The composition according to claim 1, characterized in that it comprises the following components in parts by weight: 3-5 parts of cinnamon extract, 10-20 parts of eucommia ulmoides extract, 10-20 parts of sophora flower extract, 5-10 parts of grape seed extract and 25-30 parts of cocoa extract.

3. The composition according to claim 1, wherein the weight ratio of the cinnamon extract, the eucommia ulmoides extract and the sophora japonica extract is 3-5:10-20: 10-20.

4. The composition according to claim 3, wherein the weight ratio of the cinnamon extract to the eucommia ulmoides extract to the sophora japonica extract is 4-5:12-18: 12-18.

5. The composition of claim 1, wherein the weight ratio of grape seed extract to cocoa extract is 5-10: 25-30.

6. The composition of claim 5, wherein the weight ratio of grape seed extract to cocoa extract is 6-10: 27-28.

7. Use of the composition of any one of claims 1 to 6 for the preparation of a product having a blood pressure lowering function.

8. The use according to claim 7, wherein the lowering of blood pressure is lowering Ang ii in serum, and/or lowering ET-1 in serum, and/or raising NO in serum.

9. The use according to claim 8, wherein the product is any one of a pharmaceutical product, a dietary supplement, a health food.

10. The use according to claim 7, wherein the product is in the form of any one of a tablet, a capsule and a powder.